Could a diabetes drug curb Binge-Eating? new trial aims to find out

NCT ID NCT06847399

Recruiting now Disease control Sponsor: Johns Hopkins University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether tirzepatide, a drug used for diabetes and weight loss, can reduce binge-eating episodes and help with weight loss in adults with obesity and binge-eating disorder. About 105 participants will receive tirzepatide, a placebo, or the existing drug lisdexamfetamine, plus all will get guided self-help therapy. The study compares how well each approach works over 52 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tirzepatide
What this could lead to: If it works, this could offer a new treatment option for binge-eating disorder that also helps with weight loss.
What could go wrong: This is an early phase 2 trial with only 105 participants, so results may not apply to everyone. Tirzepatide can cause side effects like nausea and vomiting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BINGE-EATING DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

binge eating disorder Binge-Eating Disorder Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BINGE-EATING DISORDER OBESITY AND OVERWEIGHT

Contacts and locations

Locations

Johns Hopkins University
RECRUITING

Baltimore, Maryland, 21146, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.